Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Search results (61)

« Back to Publications

Streamlining electronic reporting of serious adverse events (SAEs) using the REDCap data collection system: the eSAE Project.

Black J. et al, (2024), Trials, 25

Enhancing Regulatory Compliance in Research Electronic Data Capture (REDCap): the MHRAFix external module (Preprint)

Appelbe DE. et al, (2024)

Transplantation Without Overimmunosuppression (TWO) study protocol: a phase 2b randomised controlled single-centre trial of regulatory T cell therapy to facilitate immunosuppression reduction in living donor kidney transplant recipients.

Brook MO. et al, (2022), BMJ Open, 12

Intravenous iron to treat anaemia following critical care: a multicentre feasibility randomised trial.

Shah A. et al, (2022), Br J Anaesth, 128, 272 - 282

andomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks T. et al, (2021), Thorax, 76

zithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial.

Hinks TSC. et al, (2021), Lancet Respir Med, 9, 1130 - 1140

Hand Osteoarthritis: investigating Pain Effects of estrogen-containing therapy (HOPE-e): a protocol for a feasibility randomised placebo-controlled trial.

Marian IR. et al, (2021), Pilot Feasibility Stud, 7

andomised clinical trial of azithromycin versus standard care in ambulatory COVID-19 – the ATOMIC2 trial

Hinks TSC. et al, (2021)

multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.

Hinks TSC. et al, (2020), Trials, 21

nti-Tumour Necrosis Factor Therapy for Dupuytren's Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial.

Nanchahal J. et al, (2018), EBioMedicine, 33, 282 - 288

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren's disease, with an embedded dose response study.

Nanchahal J. et al, (2017), Wellcome Open Res, 2

Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to control disease progression in early Dupuytren’s disease, with an embedded dose response study.

Nanchahal J. et al, (2017), Wellcome Open Research

Integration of the Cancer-Related Pro-Inflammatory Response as a Stratifying Biomarker of Survival Benefit with Sorafenib in Hepatocellular Carcinoma

Howell J. et al, (2016), Journal of Hepatology, 64, S195 - S195

Semi-allogeneic dendritic cells can induce antigen-specific T-cell activation, which is not enhanced by concurrent alloreactivity.

Wells JW. et al, (2007), Cancer Immunol Immunother, 56, 1861 - 1873

n immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.

Chan L. et al, (2006), Cancer Immunol Immunother, 55, 1017 - 1024

Load More

1
2
3
4
5